AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant
LAM-001 is a proprietary, investigational, inhaled formulation of sirolimus, also known as rapamycin.